Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX) from its SEC filings: 2025 revenue $3.0 billion (+8% vs the year before), net margin 2%, free cash flow $269.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $3.0 billion |
| Revenue growth | +8% |
| Net income | $72.1 million |
| Net margin | 2.4% |
| Free cash flow | $269.9 million |
| Diluted EPS | $0.22 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $127.6 million |
| Long-term debt | $2.6 billion |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.